{"id":"ee756877-9049-5671-9c27-b255ecefe76a","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fcm-phosphate-frequency","predicate":"increased_risk_of","statement":"Phosphate below 2.0 mg/dL occurred in 50.8% with ferric carboxymaltose versus 0.9% with ferumoxytol; low phosphate persisted at five weeks in 29.1% versus none.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"5d94bf30-17b4-5529-8050-9ef443a048e6","mechanism_event_label":"The phosphate risk depended strongly on the iron formulation.","subject":{"id":"3f2beafe-a8b7-5242-ab5a-7e46ee7b9913","slug":"ferric-carboxymaltose","display_name":"Ferric carboxymaltose","entity_type_key":"chemical_species"},"object":{"id":"a9c2c212-3b17-56ef-a50d-ff2a9377e2a1","slug":"iron-infusion-hypophosphatemia","display_name":"Hypophosphatemia after intravenous iron","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"5d94bf30-17b4-5529-8050-9ef443a048e6","stable_key":"e13b03e1-a614-543a-ac1b-97df18cfe30d:iron-fcm-phosphate-frequency-event","event_type":"observed_intervention","label":"The phosphate risk depended strongly on the iron formulation.","description":"Phosphate below 2.0 mg/dL occurred in 50.8% with ferric carboxymaltose versus 0.9% with ferumoxytol; low phosphate persisted at five weeks in 29.1% versus none.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"860ceb18-87bd-578a-b74b-161515ac7af9","slug":"ferumoxytol","display_name":"Ferumoxytol","entity_type_key":"chemical_species"},"role":"comparator","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b28dfc54-a5ef-5f9e-ac1f-890b68e58dc3","slug":"inorganic-phosphate","display_name":"Inorganic phosphate","entity_type_key":"chemical_species"},"role":"depleted_mineral","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"3f2beafe-a8b7-5242-ab5a-7e46ee7b9913","slug":"ferric-carboxymaltose","display_name":"Ferric carboxymaltose","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"a9c2c212-3b17-56ef-a50d-ff2a9377e2a1","slug":"iron-infusion-hypophosphatemia","display_name":"Hypophosphatemia after intravenous iron","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/iron-research/30518682.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\", \"start_char\": 0, \"end_char\": 2371, \"text_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Double-blind randomized comparison with physiological substudy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Iron research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"iron","display_name":"Iron","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"1997 adults with iron-deficiency anemia; 185 in substudy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The phosphate risk depended strongly on the iron formulation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Blood and renal phosphate handling","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"nutrient_deficiency","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"dfa180dd-3793-56ae-9b5e-9a4da36d1519","evidence_kind":"source_excerpt","locator":"Lines 940-951","start_line":940,"end_line":951,"excerpt":"### iron-fcm-phosphate-frequency\nPhosphate below 2.0 mg/dL occurred in 50.8% with ferric carboxymaltose versus 0.9% with ferumoxytol; low phosphate persisted at five weeks in 29.1% versus none.\nCondition category: nutrient_deficiency\nnutrient_topic: Iron research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The phosphate risk depended strongly on the iron formulation.\norganism: 1997 adults with iron-deficiency anemia; 185 in substudy\ntissue_or_cell_type: Blood and renal phosphate handling\nexperimental_model: Double-blind randomized comparison with physiological substudy\nlimitations: Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow.\nexposure: One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up\nevidence_span: {\"source_cache\": \"artifacts/iron-research/30518682.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\", \"start_char\": 0, \"end_char\": 2371, \"text_sha256\": \"489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257\"}\n[iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","model_system":"Double-blind randomized comparison with physiological substudy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1560864c-91d1-58dc-90c4-49bf61aba3de","stable_key":"import-e13b03e1-a614-543a-ac1b-97df18cfe30d","title":"Iron: absorption, trafficking, iron-dependent enzymes and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f9dab767a21c9bbfef3227707fe3c82953536bb1335599dd4ef93b5ea2dbf03f","revision_id":"77700d7f-2902-54b9-adae-8cbc77b24682","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}